Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NutriCim: Nutritional Intervention in NSCLC
NCT05902260Completed
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial. Primary endpoint: Variability of clearance of pembrolizumab at 12 weeks. Started Jul 2021; status: completed.
Beyond the preview
Go deeper on NCT05902260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902260.